Abstract
Background
Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) plays vital roles in inflammatory and auto-immune diseases, but its correlations with disease risk and clinical features in inflammatory bowel disease (IBD) need further investigation. The present study intended to explore the correlation of ITIH4 with disease activity and inflammation, as well as its change after treatment in IBD patients.
Methods
Totally, 40 active Crohn’s disease (A-CD) patients, 40 clinical-remission CD (R-CD) patients, 40 active ulcerative colitis (A-UC) patients, 40 clinical-remission UC (R-UC) patients, and 40 health controls (HCs) were enrolled. ITIH4 in serum was assessed by ELISA.
Results
ITIH4 was lower in A-CD, R-CD, A-UC, and R-UC patients than in HCs (P < 0.001). Notably, ITIH4 reduced in A-CD patients than in R-CD patients (P = 0.017), and in A-UC patients compared with R-UC patients (P = 0.010). Besides, in A-CD patients, ITIH4 negatively correlated with tumor necrosis factor-alpha (TNF-α), interleukin (IL)-17A, IL-1β, C-reactive protein (CRP), and clinical disease activity index score (all P < 0.05). In A-UC patients, ITIH4 negatively correlated with TNF-α, IL-17A, IL-1β, IL-6, CRP, and Mayo score (all P < 0.05). However, in R-CD and R-UC patients, these correlations were less obvious than in A-CD and A-UC patients. ITIH4 was increased after treatment (all P < 0.05), and its expression at W12 after treatment was higher in response patients compared with no response patients in A-CD (P = 0.022) and A-UC groups (P = 0.038).
Conclusion
ITIH4 correlates with IBD susceptibility, active risk, inflammation level, and its elevation after treatment relates to clinical response in IBD patients.
Similar content being viewed by others
References
Abraham BP, Ahmed T, Ali T (2017) Inflammatory bowel disease: pathophysiology and current therapeutic approaches. Handb Exp Pharmacol 239:115–146
Flynn S, Eisenstein S (2019) Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am 99(6):1051–1062
Park J, Park S, Lee SA et al (2021) Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management. Korean J Intern Med 36(5):1040–1048
Wallace KL, Zheng LB, Kanazawa Y, Shih DQ (2014) Immunopathology of inflammatory bowel disease. World J Gastroenterol 20(1):6–21
Mak WY, Zhao M, Ng SC, Burisch J (2020) The epidemiology of inflammatory bowel disease: east meets west. J Gastroenterol Hepatol 35(3):380–389
Sood A, Ahuja V, Midha V et al (2020) Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intest Res 18(4):355–378
Mitoma H, Horiuchi T, Tsukamoto H, Ueda N (2018) Molecular mechanisms of action of anti-TNF-alpha agents - comparison among therapeutic TNF-alpha antagonists. Cytokine 101:56–63
Chande N, Townsend CM, Parker CE, MacDonald JK (2016) Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 10(10):CD000545
Clarke WT, Feuerstein JD (2019) Colorectal cancer surveillance in inflammatory bowel disease: practice guidelines and recent developments. World J Gastroenterol 25(30):4148–4157
Gecse KB, Vermeire S (2018) Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol 3(9):644–653
Oligschlaeger Y, Yadati T, Houben T (2019) Inflammatory bowel disease: a stressed “gut/feeling”. Cells 8(7):659
Misselwitz B, Juillerat P, Sulz MC et al (2020) Emerging treatment options in inflammatory bowel disease: Janus kinases, stem cells, and more. Digestion 101(Suppl 1):69–82
Chandler KB, Brnakova Z, Sanda M et al (2014) Site-specific glycan microheterogeneity of inter-alpha-trypsin inhibitor heavy chain H4. J Proteome Res 13(7):3314–3329
Kashyap RS, Nayak AR, Deshpande PS et al (2009) Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clin Chim Acta 402(1–2):160–163
Choi-Miura NH, Takahashi K, Yoda M et al (2000) The novel acute phase protein, IHRP, inhibits actin polymerization and phagocytosis of polymorphonuclear cells. Inflamm Res 49(6):305–310
Li L, Choi BC, Ryoo JE et al (2018) Opposing roles of inter-alpha-trypsin inhibitor heavy chain 4 in recurrent pregnancy loss. EBioMedicine 37:535–546
Osada A, Matsumoto I, Mikami N et al (2021) Citrullinated inter-alpha-trypsin inhibitor heavy chain 4 in arthritic joints and its potential effect in the neutrophil migration. Clin Exp Immunol 203(3):385–399
Kawaguchi H, Matsumoto I, Osada A et al (2018) Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis. Arthritis Res Ther 20(1):66
Gersemann M, Wehkamp J, Stange EF (2012) Innate immune dysfunction in inflammatory bowel disease. J Intern Med 271(5):421–428
Forbes A, Escher J, Hebuterne X et al (2017) ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr 36(2):321–347
Nie J, Zhao Q (2020) Lnc-ITSN1-2, derived from RNA sequencing, correlates with increased disease risk, activity and promotes CD4(+) T cell activation, proliferation and Th1/Th17 cell differentiation by serving as a ceRNA for IL-23R via sponging miR-125a in inflammatory bowel disease. Front Immunol 11:852
Farkas K, Rutka M, Golovics PA et al (2016) Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis 10(11):1273–1278
Filippi MD (2019) Neutrophil transendothelial migration: updates and new perspectives. Blood 133(20):2149–2158
Garcia-Gil FA, Lampreave F, Fuentes-Broto L et al (2010) Inter-alpha-trypsin inhibitor heavy chain 4 as a marker of acute rejection in pancreas allotransplantation in pigs. Transplant Proc 42(8):3063–3069
Shi X, Ohta Y, Liu X et al (2019) Acute anti-inflammatory markers ITIH4 and AHSG in mice brain of a novel Alzheimer’s disease model. J Alzheimers Dis 68(4):1667–1675
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Informed consent
The written informed consents were gathered from all subjects. The study was permitted by Institutional Review Board.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wen, N., Zhao, N., Xu, H. et al. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment. Ir J Med Sci 191, 2105–2111 (2022). https://doi.org/10.1007/s11845-021-02837-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-021-02837-3